Genentech's great deal


Roche will finally buy Genentech (DNA) after months of fighting over a price for the acquisition. According to The Wall Street Journal (subscription required), "Swiss drug maker Roche Holding AG said Thursday it has agreed with Genentech Inc. to buy the 44 percent of the U.S. biotech company that it doesn't already own for around $46.8 billion."

The amount is not what Genentech wanted, which was over $100 a share. But the final price was close to $95. Before the first offer from Roche, the U.S. company's stock was only $75.